Loading clinical trials…
Loading clinical trials…
Clinical trials · failure tracking
Oncology studies whose overall status is TERMINATED, WITHDRAWN or SUSPENDED on ClinicalTrials.gov, with the stop reason exactly as the registrant posted it. A category is attached only when an explicit keyword rule matches the text; CancerIndex never infers why a study stopped.
1,672 stopped studies mapped to Malignant Reproductive System Neoplasm and descendants · 89% state a reason
Over the 1,672 studies matching the cancer, status and year filters (the category filter does not change this chart). Each study is counted once, in the first matching category; greyed bars are studies whose text matched no rule or was empty.
Computedrules ci-stop-reasons-v1 · keyword matching only
A category is assigned when one of its keywords appears in the posted text (case-insensitive, whole words). Rules are tested in this order and the first match wins; every match is kept in the API (reasonMatches).
| NCT | Title | Phase | Status | First posted | Lead sponsor | Why stopped (as posted) | Category |
|---|---|---|---|---|---|---|---|
| NCT03277482 | Durvalumab, Tremelimumab + Radiotherapy in Gynecologic Cancer | Phase 1 | terminated | Sep 11, 2017 | Dana-Farber Cancer Institute | Expansion cohort was not open | Other (stated, no rule matched) |
| NCT03294694 | Ribociclib + PDR001 in Breast Cancer and Ovarian Cancer | Phase 1 | terminated | Sep 27, 2017 | Dana-Farber Cancer Institute | Safety Implications | Safety / toxicity |
| NCT02446652 | Evaluation of TRANSKRIP ® Plus Chemotherapy in Recurrent-Persistent Cervical Cancer | Phase 3 | withdrawn | May 18, 2015 | National Institute of Cancerología | Due to a lack of sufficient resources, the opening was not carried out. | Other (stated, no rule matched) |
| NCT04152018 | Study of PF-06940434 in Patients With Advanced or Metastatic Solid Tumors. | Phase 1 | terminated | Nov 5, 2019 | Pfizer | Study termination was based on strategic considerations and not due to specific safety reasons or a… | Safety / toxicity |
| NCT01673984 | GP Extended Action Triptorelin(GREAT) | Phase 4 | terminated | Aug 28, 2012 | Ipsen | The study was discontinued prematurely by the sponsor due to non-medical reasons | Other (stated, no rule matched) |
| NCT04442126 | A Study of NM21-1480 in Adult Patients With Advanced Solid Tumors | Phase 1 / Phase 2 | terminated | Jun 22, 2020 | Numab Therapeutics AG | A business decision was made to discontinue further enrollment. There were no safety concerns that… | Safety / toxicity |
| NCT05672095 | Niraparib and Selenium for the Treatment of Recurrent BRCA Negative Platinum Resistant… | Phase 1 / Phase 2 | withdrawn | Jan 5, 2023 | City of Hope Medical Center | Abandoned | Other (stated, no rule matched) |
| NCT04927663 | 11C-YJH08 PET Imaging for Detection of Glucocorticoid Receptor Expression | Phase 1 | terminated | Jun 16, 2021 | Rahul Aggarwal | Slow accrual | Enrollment / accrual |
| NCT03255252 | Assessment Study to Evaluate Specific Immune Response in Locally Advanced Cervix Cancer…(IMMUVIX) | Phase 2 | terminated | Aug 21, 2017 | Institut du Cancer de Montpellier - Val d'Aurelle | insufficient recruitment | Enrollment / accrual |
| NCT00635167 | Contrast Enhanced Transrectal Ultrasonography (TRUS) to Assess Prostatic Vascularity… | N/A | terminated | Mar 13, 2008 | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University | Closed by PI final report submitted | Other (stated, no rule matched) |
| NCT04926181 | Apalutamide Plus Cetrelimab in Patients With Treatment-Emergent Small Cell Neuroendocrine… | Phase 2 | terminated | Jun 15, 2021 | Rahul Aggarwal | Funding | Funding |
| NCT05396794 | Bariatric Education for Women With Obesity and Endometrial Cancer(SCC-BAREDU) | — | terminated | May 31, 2022 | University of Oklahoma | No Surgeon to perform the operations. | Other (stated, no rule matched) |
| NCT02756130 | Birinapant and Carboplatin in Treating Patients and Targeting Recurrent High Grade… | Phase 1 / Phase 2 | withdrawn | Apr 29, 2016 | Jonsson Comprehensive Cancer Center | funding was not secured | Funding |
| NCT03300505 | ARRx in Combination With Enzalutamide in Metastatic Castration Resistant Prostate Cancer | Phase 1 | terminated | Oct 3, 2017 | University of Michigan Rogel Cancer Center | Cancelled by the sponsor | Other (stated, no rule matched) |
| NCT03456700 | Auranofin and Sirolimus in Treating Participants With Ovarian Cancer | Phase 2 | terminated | Mar 7, 2018 | Mayo Clinic | The study is closed per results from the interim analysis. | Efficacy / futility |
| NCT05177770 | Study of SRF617 With AB928 (Etrumadenant) and AB122 (Zimberelimab) in Patients With… | Phase 2 | terminated | Jan 5, 2022 | Coherus Oncology, Inc. | The study was terminated for strategic reasons, not due to any safety concerns. | Safety / toxicity |
| NCT04607135 | ARFI Imaging for Targeted Prostate Biopsy | N/A | terminated | Oct 29, 2020 | Duke University | Current sample size sufficiently powers the study to evaluate outcome measures | Other (stated, no rule matched) |
| NCT02569957 | Effect of Acetylcysteine With Topotecan Hydrochloride on the Tumor Microenvironment in… | Phase 2 | terminated | Oct 7, 2015 | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University | The trial was halted prematurely due to slow accrual. | Enrollment / accrual |
| NCT01341288 | Robotic Seed Implantation for Prostate Cancer Brachytherapy(EUCLIDIAN) | Phase 1 | terminated | Apr 25, 2011 | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University | Slow accrual | Enrollment / accrual |
| NCT01313559 | Pasireotide (SOM230) With or Without Everolimus in Treating Patients With Hormone… | Phase 2 | terminated | Mar 11, 2011 | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University | Slow accrual | Enrollment / accrual |
| NCT05462249 | Impact of Catch-up HPV Vaccination(HPVAC2) | — | terminated | Jul 18, 2022 | University Hospital, Brest | overestimation of the number of healthcare professionals participating in the inclusions | Other (stated, no rule matched) |
| NCT03076242 | Genetic Evaluation of Men (GEM) | — | terminated | Mar 10, 2017 | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University | Competing trial | Other (stated, no rule matched) |
| NCT03477864 | Stereotactic Body Radiation Therapy With REGN2810 and/or Ipilimumab Before Surgery in… | Phase 1 | withdrawn | Mar 26, 2018 | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University | Study was not accruing | Enrollment / accrual |
| NCT04483544 | Pembrolizumab and Olaparib in Cervical Cancer Patients | Phase 2 | terminated | Jul 23, 2020 | Baptist Health South Florida | Poor accrual related to change in standard of care treatment for this population. | Enrollment / accrual |
| NCT05819827 | Associations Between Chemotherapy-Induced Nausea in Patients With Genitourinary, Sarcoma… | — | terminated | Apr 19, 2023 | Mayo Clinic | Low/slow accrual | Enrollment / accrual |
| NCT06795178 | Efficacy, Safety, and Pharmacokinetics of FP-014, 11.25 mg in Patients With Advanced…(KATANA E3M) | Phase 3 | withdrawn | Jan 27, 2025 | Foresee Pharmaceuticals Co., Ltd. | Business reasons not safety related. | Safety / toxicity |
| NCT06795191 | Efficacy, Safety, and Pharmacokinetics of FP-014, 22.5 mg in Patients With Advanced…(KATANA E6M) | Phase 3 | withdrawn | Jan 27, 2025 | Foresee Pharmaceuticals Co., Ltd. | Business reasons not safety related. | Safety / toxicity |
| NCT06106633 | Pain Reduction and Ovarian Perfusion Following Uterine Fibroid Embolization(PEDD-UFE) | N/A | terminated | Oct 30, 2023 | Massachusetts General Hospital | Insufficient Enrollment | Enrollment / accrual |
| NCT03581500 | Hyperpolarized Carbon C 13 Pyruvate Magnetic Resonance Spectroscopic Imaging in… | Phase 2 | withdrawn | Jul 10, 2018 | M.D. Anderson Cancer Center | Committee could not find that the regulatory approval are met to re-approve this study. | Other (stated, no rule matched) |
| NCT04301011 | Study of TBio-6517 Given Alone or in Combination With Pembrolizumab in Solid Tumors(RAPTOR) | Phase 1 | terminated | Mar 9, 2020 | Turnstone Biologics, Corp. | Sponsor decision | Sponsor / business decision |
| NCT04514692 | Bone Marrow Sparing Image-Guided Radiation Therapy (RT) Incorporating Novel Use of GCSF… | Phase 1 / Phase 2 | terminated | Aug 17, 2020 | Stanford University | Lack of funding | Funding |
| NCT04875806 | A Safety and Tolerability Study of NC762 in Subjects With Advanced or Metastatic Solid… | Phase 1 / Phase 2 | terminated | May 6, 2021 | NextCure, Inc. | Due to the limited activity in Phase 1, NextCure decided to discontinue development of the… | Other (stated, no rule matched) |
| NCT04278326 | Primary Organoid Models and Combined Nucleic Acids Therapeutics for Anti-HPV Treatments(ORGANOIDES) | N/A | terminated | Feb 20, 2020 | Centre Hospitalier Régional d'Orléans | the partner laboratory encountered various difficulties (COVID, relocation of the laboratory,… | COVID-19 / pandemic |
| NCT03610490 | Autologous Tumor Infiltrating Lymphocytes MDA-TIL in Treating Patients With Recurrent or… | Phase 2 | terminated | Aug 1, 2018 | M.D. Anderson Cancer Center | Lack of Efficacy | Efficacy / futility |
| NCT05179239 | A Study of SHR-1701 Plus Platinum-containing Chemotherapy With or Without BP102… | Phase 3 | terminated | Jan 5, 2022 | Suzhou Suncadia Biopharmaceuticals Co., Ltd. | Sponsor develops strategy adjustment | Sponsor / business decision |
| NCT03764540 | Docetaxel Versus Cabazitaxel Post Abiraterone or Enzalutamide(CABPOSTAAT) | Phase 2 | terminated | Dec 5, 2018 | Centre hospitalier de l'Université de Montréal (CHUM) | The cabazitaxel was recently approved by the regulatory authorities for mCRPCa | Other (stated, no rule matched) |
| NCT05815316 | 18F-PSMA PET/MRI for the Diagnosis of Clinically Significant Prostate Cancer | Phase 2 | withdrawn | Apr 18, 2023 | IRCCS San Raffaele | error in the registration on clincialtrials.gov. The same clinical trial has been correctly… | Other (stated, no rule matched) |
| NCT04556617 | PLX2853 in Combination With Abiraterone Acetate and Prednisone and in Combination With… | Phase 1 / Phase 2 | terminated | Sep 21, 2020 | Opna Bio LLC | study terminated due to business realignment | Sponsor / business decision |
| NCT04067544 | Acupuncture Treatment of Chemotherapy-Induced Peripheral Neuropathy in Women | N/A | terminated | Aug 26, 2019 | University of Utah | Unforeseen complications due to COVID-19 and funding | COVID-19 / pandemic |
| NCT05126342 | Study to Estimate Efficacy of Combining Dostarlimab and Niraparib in Relapsed EOC After… | Phase 2 | withdrawn | Nov 19, 2021 | AGO Research GmbH | Study has been withdrawn; was never submitted to Competent authority nor to ethics commitee. | Other (stated, no rule matched) |
| NCT03527264 | BrUOG 355: Nivolumab to Tailored Radiation Therapy With Concomitant Cisplatin in the… | Phase 2 | terminated | May 17, 2018 | Brown University | Slow enrollment | Enrollment / accrual |
| NCT04383210 | Study of Seribantumab in Adult Patients With NRG1 Gene Fusion Positive Advanced Solid… | Phase 2 | terminated | May 12, 2020 | Elevation Oncology | Business decision | Sponsor / business decision |
| NCT03829501 | A Phase 1/2, Open-label, Multi-center Study of the Safety and Efficacy of Alomfilimab… | Phase 1 / Phase 2 | terminated | Feb 4, 2019 | Kymab Limited | Early discontinuation based on strategic sponsor decision not driven by any safety concerns. | Safety / toxicity |
| NCT06375629 | ES-HIFU, Prospective Data Collection of Patients Treated With Partial Gland HIFU Ablation…(ES-HIFU) | — | terminated | Apr 19, 2024 | EDAP TMS S.A. | The study was terminated early to integrate sites into a larger registry for a more comprehensive… | Safety / toxicity |
| NCT05208229 | The Role of WB-MRI in the Evaluation of Prostate Cancer Patients Treated With Lutetium -…(WB-LuPSMA) | — | terminated | Jan 26, 2022 | Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS | The study was linked to another protocol that is over | Other (stated, no rule matched) |
| NCT06094842 | Autologous T Cells Lentivirally Transduced to Express L1CAM-Specific Chimeric Antigen… | Phase 1 | withdrawn | Oct 23, 2023 | Fred Hutchinson Cancer Center | Study closed before opening to accrual | Enrollment / accrual |
| NCT06385548 | Efficacy and Safety Study of Lurbinectedin and Dostarlimab in Cancer Patients: Protocol…(LiDer) | Phase 1 / Phase 2 | withdrawn | Apr 26, 2024 | Vall d'Hebron Institute of Oncology | IMP owner decision | Other (stated, no rule matched) |
| NCT05192850 | Endometrial Cancer Recurrence in Patients Taking Metformin | — | withdrawn | Jan 14, 2022 | WellSpan Health | study was not started at WellSpan | Other (stated, no rule matched) |
| NCT03585764 | MOv19-BBz CAR T Cells in aFR Expressing Recurrent High Grade Serous Ovarian, Fallopian… | Phase 1 | terminated | Jul 13, 2018 | University of Pennsylvania | This study was halted prematurely due to recruitment barriers | Enrollment / accrual |
| NCT02641639 | FOCUS: PCC + Bevacizumab + CA4P Versus PCC + Bevacizumab + Placebo for Subjects With… | Phase 2 / Phase 3 | terminated | Dec 29, 2015 | Mateon Therapeutics | The study was terminated early due to the lack of efficacy and the study sponsor's decision to no… | Efficacy / futility |
Stop reasons are registrant-reported free text and are displayed verbatim (truncated; hover for the full text). Categories come from explicit keyword rules and are never inferred from the study design, sponsor or outcome; a study that stopped for several reasons is filed under the first rule that matched. A TERMINATED status does not imply a negative result.
Data updated 23 days agoSource updated May 31, 2025source: clinicaltrials